10-Q/A: Bio Essence Corp. Reports Mixed Q2 2024 Results Amid Restructuring and Going Concern Concerns

Bio Essence Corp.'s Q2 2024 results reveal a net loss despite increased revenues from continuing operations and gains from discontinued operations, raising concerns about the company's ability to continue as a going concern.

Summary

• Bio Essence Corp. filed its Second Amendment to Form 10-Q for the period ended June 30, 2024, to update a disclosure regarding the company's internal controls.
• The company reported revenues of $41,695 from continuing operations for the six months ended June 30, 2024, compared to $0 in the same period last year.
• The net loss from continuing operations for the six months ended June 30, 2024, was $338,665, compared to a net loss of $116,507 for the same period in 2023.
• The company had a net loss of $81,740 for the six months ended June 30, 2024, which includes a net gain of $256,925 from discontinued operations, compared to a net loss of $463,351 for the same period in 2023.
• Bio Essence sold its subsidiaries BEP and BEH for $300,000 and $400,000, respectively, and dissolved McBE Pharma Inc.
• The company's management has expressed substantial doubt about its ability to continue as a going concern due to recurring net losses and an accumulated deficit of $9,222,214 as of June 30, 2024.
• Management intends to raise funds through private or public offerings or by obtaining loans.
• As of June 30, 2024, the company's current liabilities exceeded current assets, resulting in a working capital deficit of $2,192,611 and a current ratio of 0.29:1.
• The company's principal source of funds is loans from an officer who is also a major shareholder.
• The company believes it will need $1.2 million in cash to continue its current business for the next 12 months.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the company's recurring losses, going concern warning, and weak liquidity position. While there were some positive developments, such as increased revenues and gains from discontinued operations, the overall financial health of the company remains a significant concern.

Positives

• Revenues from continuing operations increased to $41,695 for the six months ended June 30, 2024, compared to $0 in the same period last year.
• The company recorded a net gain of $256,925 from discontinued operations.
• Net loss improved to $81,740 compared to $463,351 for the same period last year.
• The company successfully sold its subsidiaries BEP and BEH for a combined $700,000.

Negatives

• The company incurred a net loss of $338,665 from continuing operations for the six months ended June 30, 2024.
• The company has an accumulated deficit of $9,222,214 from continuing operations as of June 30, 2024.
• Management has expressed substantial doubt about the company's ability to continue as a going concern.
• The company's current liabilities exceed current assets, resulting in a working capital deficit of $2,192,611 and a low current ratio of 0.29:1.
• The company forfeited a $50,000 security deposit due to early termination of a lease.

Risks

• The company's ability to continue as a going concern is uncertain due to recurring net losses and a significant accumulated deficit.
• The company's liquidity position is weak, with current liabilities exceeding current assets.
• The company is dependent on loans from a major shareholder, which may not be a sustainable source of funding.
• The company's internal controls over financial reporting were not effective as of June 30, 2024.
• The company needs to secure additional financing of $1.2 million to continue operations for the next 12 months.

Future Outlook

Management intends to raise funds through private or public offerings or by obtaining loans to address the company's liquidity concerns and continue operations.

Management Comments

• Management has expressed substantial doubt about the company's ability to continue as a going concern.
• Management intends to raise additional funds by way of a private or public offering, or by obtaining loans from banks or others.
• Management believes it will need $1.2 million cash to continue its current business for the next 12 months.

Industry Context

The health supplement industry is highly competitive, and Bio Essence faces challenges in maintaining profitability and securing funding. The company's restructuring efforts, including the sale of subsidiaries, reflect a strategic shift to focus on core operations and improve financial stability.

Comparison to Industry Standards

• It is difficult to compare Bio Essence Corp.'s results directly to industry standards due to its small size and specific circumstances.
• Larger, more established companies in the health supplement industry, such as Herbalife Nutrition and Amway, typically have more diversified revenue streams and stronger balance sheets.
• Bio Essence's reliance on loans from a major shareholder is not a typical financing strategy for publicly traded companies and may indicate limited access to traditional capital markets.
• The company's negative working capital and low current ratio are below industry benchmarks and raise concerns about its short-term financial health.

Related Party Transactions

• At June 30, 2024 and December 31, 2023, the Company held loans from one major shareholder (also the Company's senior officer) for $1,365,246 and $1,180,046, respectively.
• At June 30, 2024 and December 31, 2023, the Company held loan from another major shareholder for $608,631 for settling the litigation.
• On May 31, 2023, the Board of Directors of the Company, approved a debt-to-equity conversion.

Stakeholder Impact

• Shareholders face the risk of dilution if the company raises capital through equity offerings.
• Employees may be affected by potential cost-cutting measures or restructuring efforts.
• Customers may experience disruptions in product availability or service quality if the company's financial difficulties persist.
• Suppliers and creditors face the risk of delayed payments or potential losses if the company is unable to meet its financial obligations.

Next Steps

• The company plans to increase its income by strengthening its sales force, providing attractive sales incentive programs, and increasing marketing and promotion activities.
• The company will explore options to provide additional financing to fund future operations, including securing lines of credit, sales of debt or equity securities, loans and cash advances from third parties or banks, and other similar actions.

Key Dates

Keywords

financial statements, going concern, net loss, revenues, discontinued operations, liquidity, internal controls, Bio Essence Corp, 10-Q, financial reporting